** Shares of Biotechnology company YD Bio YDES.O rise 3.97% to $8.38 premarket

** Co says it signed a U.S. regulatory partnership with YC Biotech, an Asia‑based technical and regulatory support firm, to help drug and device makers navigate FDA approvals

** Co says it will act as YC Biotech's exclusive U.S. representative, handling FDA communication and guiding clients from early meetings to final submissions

** YDES says the deal marks a shift toward a broader platform model that may expand into Europe

** Co says partnership expected to boost service offerings and support client growth

** Shares up ~8% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))